Literature DB >> 7535875

Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients.

P Atkison1, G Joubert, A Barron, D Grant, K Paradis, E Seidman, W Wall, H Rosenberg, J Howard, S Williams.   

Abstract

Reported side-effects of tacrolimus, a potent immunosuppressive agent, have not included cardiotoxicity. We describe 5 consecutive paediatric transplant recipients (3 small bowel with or without liver and 2 liver) who received tacrolimus. 2 developed congestive heart failure and hypertrophic obstructive cardiomyopathy which resolved after changing to cyclosporin. In the other 3 patients the cardiomyopathy regressed or improved with a lower dose of tacrolimus or after stopping the drug.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535875     DOI: 10.1016/s0140-6736(95)90011-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  29 in total

1.  Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2016-02-16       Impact factor: 6.047

Review 2.  Causality assessment of adverse effects: when is re-challenge ethically acceptable?

Authors:  A L Po; M J Kendall
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus.

Authors:  A Khanna; A Jain; G Ziady; A J Demetris; J J Fung; D Kramer; T E Starzl
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

4.  CMR-derived extracellular volume fraction (ECV) in asymptomatic heart transplant recipients: correlations with clinical features and myocardial edema.

Authors:  Yating Yuan; Jie Cai; Yue Cui; Jing Wang; Osamah Alwalid; Xuehua Shen; Yukun Cao; Yan Zou; Bo Liang
Journal:  Int J Cardiovasc Imaging       Date:  2018-07-28       Impact factor: 2.357

5.  Reverse ventricular remodeling and improved ventricular compliance after heart transplantation in infants and young children.

Authors:  Kanwal M Farooqi; Leo Lopez; Robert H Pass; Daphne T Hsu; Jacqueline M Lamour
Journal:  Pediatr Cardiol       Date:  2014-02-09       Impact factor: 1.655

6.  Effects of the immunosuppressant FK506 on intracellular Ca2+ release and Ca2+ accumulation mechanisms.

Authors:  G Bultynck; P De Smet; A F Weidema; M Ver Heyen; K Maes; G Callewaert; L Missiaen; J B Parys; H De Smedt
Journal:  J Physiol       Date:  2000-06-15       Impact factor: 5.182

7.  Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 8.  Conversion from cyclosporin to tacrolimus in paediatric liver transplant recipients.

Authors:  G V Mazariegos; A A Salzedas; A Jain; J Reyes
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

9.  Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells.

Authors:  László Szabó; Norbert Szentandrássy; Kornél Kistamás; Bence Hegyi; Ferenc Ruzsnavszky; Krisztina Váczi; Balázs Horváth; János Magyar; Tamás Bányász; Balázs Pál; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-19       Impact factor: 3.000

10.  Small bowel transplantation. A life-saving option for selected patients with intestinal failure.

Authors:  S Asfar; P Atkison; C Ghent; J Duff; W Wall; S Williams; E Seidman; D Grant
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.